NuVasive sets IPO (initial public offering) for up to $97 million
This article was originally published in Clinica
Executive Summary
NuVasive, a spinal technology developer whose financial backers include Johnson & Johnson Development Corporation and William Blair Capital Partners, has set $97.1m as the new upper limit for its impending initial public offering on Nasdaq. In March the company filed a registration statement with the SEC for a maximum upper limit of $92m (see Clinica No 1099, p 16).